BiotechTube

Enobosarm + Semaglutide

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle Loss

Conditions

Muscle Loss, Obesity

Trial Timeline

Apr 29, 2024 → Aug 22, 2025

NCT ID
NCT06282458

About Enobosarm + Semaglutide

Enobosarm + Semaglutide is a phase 2 stage product being developed by Veru for Muscle Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT06282458. Target conditions include Muscle Loss, Obesity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06282458Phase 2Completed

Competing Products

20 competing products in Muscle Loss

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
77
EperisoneEisaiPhase 3
77
LY2495655 + PlaceboEli LillyPhase 2
52
HRS-9190Jiangsu Hengrui MedicinePhase 1
33
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
33
Botulinum Toxin Type AAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
BOTOX + Placebo for BOTOXAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
Durvalumab + Tremelimumab + Enfortumab VedotinAstraZenecaPhase 3
77
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
77
Durvalumab + OleclumabAstraZenecaPhase 1
33
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + SelumetinibAstraZenecaPhase 1
33
Durvalumab + Cisplatin + GemcitabineAstraZenecaPhase 3
77
Durvalumab + BCGAstraZenecaPhase 3
77
Durvalumab + MonalizumabAstraZenecaPhase 2
52

Other Products from Veru

VERU-111 + Enzalutamide, AbirateronePhase 3
69
VERU-111Phase 3
69
Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or FulvestrantPhase 3
69
Enobosarm + ExemestanePhase 3
69
Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulatorPhase 2
44